Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice
暂无分享,去创建一个
A. Gasbarrini | M. Zoli | F. Piscaglia | F. Marra | E. Giannini | F. Farinati | M. Di Marco | E. Caturelli | R. Sacco | G. Cabibbo | F. Foschi | A. Masotto | G. Nardone | F. Trevisani | A. Olivani | F. Morisco | M. Bernardi | A. Colecchia | F. Ciccarese | L. Bucci | F. Garuti | B. Lenzi | F. Borzio | R. Virdone | M. Felder | L. Benvegnu' | G. Svegliati Baroni | M. Brunacci | M. Valente | G. Rapaccini
[1] J. Heo,et al. Effect of yttrium‐90 radioembolization on outcomes in Asian patients with early to advanced stage hepatocellular carcinoma , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.
[2] A. Gasbarrini,et al. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[3] A. Gasbarrini,et al. The evolutionary scenario of hepatocellular carcinoma in Italy: an update , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[4] H. El‐Serag,et al. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. , 2016, Journal of hepatology.
[5] Y. Won. Korea Central Cancer Registry , 2016 .
[6] M. Kudo,et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. , 2016, Journal of hepatology.
[7] M. Zoli,et al. A Liver Index and its Relationship to Indices of HCC Aggressiveness , 2016, Journal of integrative oncology.
[8] S. Ahn,et al. Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database , 2016, Journal of gastroenterology and hepatology.
[9] H. Tengg-Kobligk,et al. Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm. , 2015, Annals of hepatology.
[10] L. Bolondi,et al. Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate-advanced hepatocellular carcinoma. , 2015, Future oncology.
[11] M. Colombo,et al. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib , 2015, Hepatology.
[12] B. Daniele,et al. Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. , 2015, Future oncology.
[13] D. Sinn,et al. Different Survival of Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Patients by the Extent of Portal Vein Invasion and the Type of Extrahepatic Spread , 2015, PloS one.
[14] A. Cucchetti,et al. Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? , 2013, World journal of gastroenterology.
[15] J. Bruix,et al. Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second‐line trial design , 2013, Hepatology.
[16] R. Bruno,et al. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[17] William M. Lee,et al. Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail? , 2013, The American Journal of Gastroenterology.
[18] Chia-Yang Hsu,et al. Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system , 2013, Hepatology.
[19] V. Mazzaferro,et al. Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions , 2012, Seminars in Liver Disease.
[20] C. Porta,et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. , 2012, Journal of hepatology.
[21] C. Verslype,et al. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] O. B. D. de Muckadell,et al. Incidence, etiology and mortality of cirrhosis: a population-based cohort study , 2012, Scandinavian journal of gastroenterology.
[23] M. Colombo,et al. Field‐practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy , 2011, Hepatology.
[24] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[25] Xianglin L. Du,et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States , 2010, Hepatology.
[26] P. Chow,et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. , 2009, The Lancet. Oncology.
[27] V. Maizes,et al. Integrative medicine and patient-centered care. , 2009, Explore.
[28] S. Paggi,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[29] Francesco Donato,et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.
[30] R. Groszmann,et al. American association for the study of liver diseases , 1992 .
[31] G. Dusheiko,et al. Management of hepatocellular carcinoma. , 1992, Journal of hepatology.
[32] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[33] R. Pugh,et al. Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.
[34] G. Práctica,et al. European Association for the Study of the Liver , 1971 .
[35] J. Llovet,et al. Medical therapies for hepatocellular carcinoma: a critical view of the evidence , 2013, Nature Reviews Gastroenterology &Hepatology.
[36] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[37] E. Santibañes,et al. [Multimodal treatment of hepatocellular carcinoma]. , 2001, Acta gastroenterologica Latinoamericana.